Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

PURPOSE: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. OBSERVATIONS: A 68-year-old man...

Descripción completa

Detalles Bibliográficos
Autores principales: Field, Matthew G., Boldt, H. Culver, Abu Hejleh, Taher, Binkley, Elaine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899229/
https://www.ncbi.nlm.nih.gov/pubmed/35265776
http://dx.doi.org/10.1016/j.ajoc.2022.101459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899229/
https://www.ncbi.nlm.nih.gov/pubmed/35265776
http://dx.doi.org/10.1016/j.ajoc.2022.101459

Ejemplares similares